GlassScriptPhysician profile
Christy Socha
NPI 1609849728
$6,052.41
in general payments reported to CMS, 2019-2025
23 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 95% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,106 · 2022: $1,387 · 2023: $1,479 · 2024: $1,069 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.73 |
| Education | $247.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,053.62 | 2021-2025 | |
| Janssen Biotech, INC. | $560.59 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $428.07 | 2021-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $396.48 | 2023-2025 | Sotyktu |
| Pfizer INC. | $376.18 | 2021-2024 | |
| Leo Pharma INC. | $300.94 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $272.75 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $253.05 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $197.75 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $194.03 | 2021-2025 | Opzelura |
| Genzyme Corporation | $171.87 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.55 | 2021-2023 | Jublia |
| Novartis Pharmaceuticals Corporation | $131.05 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $121.43 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $105.07 | 2021-2025 | Aklief, Nemluvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $100.92 | 2021-2023 | |
| Ucb, INC. | $75.91 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $42.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.02 | 2023 | Spevigo, Cyltezo |
| Epi Health, LLC | $23.30 | 2022 | |
| Glaxosmithkline, LLC. | $22.17 | 2022 | |
| Journey Medical Corporation | $16.20 | 2023 | |
| Organon LLC | $8.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Socha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.